Weight Regain

Weight Regain

Weight regain is one of the most significant challenges in obesity treatment, occurring in the majority of individuals who achieve clinically meaningful weight loss through lifestyle intervention, pharmacotherapy, or even bariatric surgery. After weight loss, the body initiates a coordinated set of counter-regulatory responses designed to restore energy reserves to their previous set point. These include reductions in resting metabolic rate (metabolic adaptation), increased hunger-promoting hormones such as ghrelin, decreased satiety hormones such as leptin and GLP-1, and enhanced neural reward responses to food cues—all of which persist for months to years after weight loss.

Clinical data from GLP-1 receptor agonist trials have demonstrated that weight regain occurs rapidly upon treatment discontinuation. In the STEP 1 trial extension with semaglutide, participants regained approximately two-thirds of their lost weight within one year of stopping treatment. This finding underscores the chronic, relapsing nature of obesity as a disease and supports the concept that long-term pharmacotherapy may be necessary to maintain weight loss, much as chronic medication is accepted for hypertension or hyperlipidemia.

For retatrutide, weight regain dynamics remain an important area of investigation. The Phase 2 obesity trial showed that weight loss was still accelerating at 48 weeks in the higher dose groups, suggesting that steady-state weight had not yet been reached. Understanding the trajectory of weight regain after retatrutide discontinuation, and the potential for lower maintenance doses to sustain weight loss, will be critical for defining long-term treatment strategies. These questions are expected to be addressed in extension studies and dedicated maintenance trials within the broader TRIUMPH clinical development program.